Login to Your Account

In The Clinic NEWS
A shipping glitch that might have chilled to near freezing study packages of Ampio Pharmaceuticals Inc.'s late-stage osteoarthritis of the knee treatment, Ampion, will delay analysis of data from a pivotal study of the drug, the company said.
Baxter International Inc. unveiled favorable phase III data from the pivotal trial with BAX 855, an extended half-life recombinant factor VIII (rFVIII) antagonist for hemophilia A. 

Shares of Novabay Pharmaceuticals Inc. plunged 44 percent, to a one-year low of 69 cents, Wednesday morning after the company reported that its NVC-422 (auriclosene) ophthalmic formulation failed to meet the primary and secondary endpoints in a phase II study.

More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: